Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant subline
- PMID: 2171796
- DOI: 10.1007/BF02994093
Ability of four potential topoisomerase II inhibitors to enhance the cytotoxicity of cis-diamminedichloroplatinum (II) in Chinese hamster ovary cells and in an epipodophyllotoxin-resistant subline
Abstract
Four drugs known to interact with topoisomerase II were assessed for their ability to enhance the cytotoxicity of cis-diamminedichloroplatinum(II) (CDDP) in Chinese hamster ovary (CHO) cell lines sensitive and resistant to VM-26. The combination treatments were analyzed by isobologram methodology. On 24 h exposure, there was no significant difference in the cytotoxicity of novobiocin or ciprofloxacin toward either cell line. The resistant cells were approximately 9-fold more resistant to 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and approximately 170-fold more resistant to etoposide after a 24-h exposure. The combination of novobiocin and cisplatin produced greater than additive cell kill over the entire dose range of cisplatin tested in both cell lines. m-AMSA and CDDP produced cell kill that fell within the envelope of additivity. Etoposide and CDDP resulted in cytotoxicity that was slightly greater than additive at low CDDP concentrations and additive at the highest concentration of CDDP tested in the parental cell line and was slightly greater than additive in the resistant cell line. Ciprofloxacin and CDDP, like novobiocin, resulted in greater than additive cell kill in both cell lines. The enhancement of CDDP cytotoxicity by novobiocin that was seen in exponentially growing cells was lost in stationary-phase cultures. In these studies, novobiocin and, to a lesser degree, ciprofloxacin produced greater than additive cell kill in combination with CDDP in parental and epipodophyllotoxin-resistant CHO cells.
Similar articles
-
Novobiocin enhances alkylating agent cytotoxicity and DNA interstrand crosslinks in a murine model.J Clin Invest. 1987 May;79(5):1524-8. doi: 10.1172/JCI112983. J Clin Invest. 1987. PMID: 3033027 Free PMC article.
-
Increased expression of glutathione S-transferase gene in cis-diamminedichloroplatinum(II)-resistant variants of a Chinese hamster ovary cell line.Cancer Res. 1989 Dec 15;49(24 Pt 1):7020-5. Cancer Res. 1989. PMID: 2479474
-
Effect of novobiocin on cisplatin cytotoxicity and DNA interstrand cross-link formation in a cisplatin-resistant, small-cell lung carcinoma cell line.Int J Cancer. 1993 Jan 2;53(1):110-7. doi: 10.1002/ijc.2910530121. Int J Cancer. 1993. PMID: 8380054
-
Proliferation dependence of topoisomerase II mediated drug action.Biochemistry. 1986 Apr 22;25(8):2248-56. doi: 10.1021/bi00356a060. Biochemistry. 1986. PMID: 3011082
-
Cytogenetical characterization of Chinese hamster ovary X-ray-sensitive mutant cells, xrs 5 and xrs 6. IV. Study of chromosomal aberrations and sister-chromatid exchanges by restriction endonucleases and inhibitors of DNA topoisomerase II.Mutat Res. 1989 Jun;212(2):137-48. doi: 10.1016/0027-5107(89)90064-x. Mutat Res. 1989. PMID: 2543922
Cited by
-
Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.J Cancer Res Clin Oncol. 1993;119(11):645-51. doi: 10.1007/BF01215982. J Cancer Res Clin Oncol. 1993. PMID: 8394365 Free PMC article.
-
Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.Cancer Chemother Pharmacol. 1993;32(6):455-62. doi: 10.1007/BF00685890. Cancer Chemother Pharmacol. 1993. PMID: 8258194
-
Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors.Cancer. 2009 Feb 1;115(3):655-64. doi: 10.1002/cncr.24054. Cancer. 2009. PMID: 19117350 Free PMC article. Clinical Trial.
-
Modulation of cis-diamminedichloroplatinum(II) resistance: a review.Br J Cancer. 1992 Aug;66(2):227-38. doi: 10.1038/bjc.1992.249. Br J Cancer. 1992. PMID: 1503895 Free PMC article. Review.
-
Tolerability and efficacy of GM-CSF [Leucomax] in patients with small cell lung cancer treated with intensive chemotherapy.Med Oncol. 1996 Dec;13(4):199-205. doi: 10.1007/BF02990932. Med Oncol. 1996. PMID: 9152970